CDIAG

CDIAG is an investigational **co-administration chemotherapy regimen** for relapsed or refractory acute myeloid leukemia. It combines the epigenetic agents chidamide, a histone deacetylase inhibitor, and decitabine, a DNA methyltransferase inhibitor, with low-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor. The regimen was evaluated as a double epigenetic-priming approach in a Phase 2 study sponsored by The First Affiliated Hospital of Soochow University; the published study enrolled 35 patients and reported a complete remission rate of 42.9% and median overall survival of 11.7 months. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.726926/full))

Other names

CDIAG regimenchidamide + decitabine + cytarabine + idarubicin + granulocyte colony-stimulating factordouble epigenetic priming regimen